Welcome to our dedicated page for SS Innovations SEC filings (Ticker: SSII), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SS Innovations International Inc. filings document a Nasdaq-listed surgical robotics issuer and its formal disclosures around the SSi Mantra platform. Recent Current Reports on Form 8-K record product and regulatory updates, telesurgery announcements, conference-related disclosures, financial-results releases and Regulation FD communications.
The filing record also covers capital structure events, including an unregistered private placement of common stock, and identifies the company’s common stock as registered on Nasdaq under SSII. Annual-report and current-report disclosures provide formal context for operating results, product development, clinical and regulatory timelines, forward-looking statements, and the company’s subsidiary-based reporting perimeter.
SS Innovations International (SSII) furnished an updated October 2025 Company Presentation under Item 7.01 (Regulation FD). The presentation is attached as Exhibit 99.1 and is intended for communications with shareholders and the investment community.
The information is deemed “furnished” rather than “filed,” meaning it is not subject to Section 18 liability and is not incorporated by reference into other Securities Act or Exchange Act filings. The report also includes standard forward‑looking statements cautionary language.
Amar Naveen Kumar is reported as an officer (CFO) and director of SS Innovations International, Inc. (SSII). The Form 3 shows no beneficial ownership of the issuer's common stock and no derivative holdings are disclosed. The filing provides the reporting person's address in Fort Lauderdale, FL and includes the required signature attestation.
SS Innovations International, Inc. reported that it has successfully completed a human factors validation study for its SSi Mantra surgical robotic system at Johns Hopkins Hospital in September 2025. The company also stated that it anticipates submitting a 510(k) premarket notification to the U.S. Food and Drug Administration for SSi Mantra for multiple specialty indications in the fourth quarter of 2025. These steps mark progress in the company’s effort to bring its surgical robotic system to the U.S. market, although regulatory clearance has not yet been obtained.
SS Innovations International, Inc. appointed Naveen Kumar Amar as its new Chief Financial Officer, effective September 24, 2025. The change was disclosed in a current report and accompanied by a press release and a formal employment agreement.
Mr. Amar, age 49, brings over 27 years of global corporate finance experience across accounting, audits, capital raising, compliance, taxation, mergers and acquisitions and investor relations. His background includes senior roles at SpiceExpress (the cargo unit of SpiceJet Ltd.), Munchado India, MSD Wellcome Trust Hilleman Laboratories, EDirect Proprietary Ltd. and GE India, and he is both a Chartered Accountant and Company Secretary in India.
The Company and Mr. Amar entered into a five-year employment agreement that provides for a base annual salary of approximately US$163,000, based on current Indian rupee to U.S. dollar exchange rates, and includes customary confidentiality, intellectual property, non-competition and non-solicitation provisions.
SS Innovations International, Inc. reported that the world’s first pediatric pyeloplasty telesurgery was successfully performed using its SSi Mantra surgical robotic system. This means a complex kidney-related procedure in a child was carried out remotely with the help of the company’s robot-assisted platform, highlighting a significant technical and clinical milestone for its technology. The company furnished a press release with additional details as an exhibit to this report.
SS Innovations International, Inc. reported a technology milestone, disclosing that it successfully completed the first robotic telesurgery performed from its bus mobile robotic telesurgery unit. This procedure was announced in a company press release and highlights the use of its robotic system in a mobile, remote-surgery setting. The press release describing the event is filed as an exhibit to the report.
Insider transactions reported for SS Innovations International, Inc. (SSII) by Sudhir Srivastava, Chairman and CEO. The filing shows two non-derivative transactions in early September 2025: on 09/03/2025 Mr. Srivastava was reported as acquiring 2,500 shares, and on 09/05/2025 he was reported as disposing of 105,000 shares. After these transactions, the total shares beneficially owned attributable to Mr. Srivastava through Sushruta Pvt. Ltd. is reported as 112,583,014 shares. The form states the holdings are indirect because the reporting person has a controlling interest in Sushruta Pvt. Ltd.
Sudhir Srivastava, identified as a Director, 10% owner and the company's Chairman and CEO, reported a series of non-derivative transactions in the common stock of SS Innovations International, Inc. (SSII) executed through an entity he controls, Sushruta Pvt. Ltd. The Form 4 shows multiple acquisitions and dispositions between 05/12/2025 and 08/11/2025, including total reported acquisitions of 60,000 shares and total reported dispositions of 111,000 shares. After the last reported transaction the beneficial ownership held indirectly by Sushruta Pvt. Ltd. is shown as 112,685,514 common shares. Table II (derivative securities) contains no entries. The filing includes an explanatory note that the reporting person has a controlling interest in Sushruta Pvt. Ltd., which holds the securities of record.
What happened: SS Innovations reported strong sales growth this quarter and in the first half of 2025, driven by system and instrument sales. Total revenue for the quarter was $10.0M and for the first six months $15.1M. Gross profit rose and operating results improved to a small positive operating income for the quarter, and the company completed an uplisting to NASDAQ.
Why it matters: The company boosted cash to $17.6M after financings and conversions, which helps near-term operations, but it still reported a $5.94M net loss for the first half and a small quarterly net loss after tax. Management discloses substantial doubt about the company’s ability to continue as a going concern and notes dependence on related-party financing and convertible note conversions.